Pathologic Evaluation in Patients Undergoing Liver Transplantation

Document Type : Original Article

Authors

1 Assistant Professor of Pathology, Department of Pathology, School of Medicine, Tabriz University of Medical Sciences, Tabriz, Iran

2 Assistant Professor of Radiotherapy, Department of Radiology, School of Medicine, Tabriz University of Medical Sciences, Tabriz, Iran

3 Assistant Professor of Surgery, Department of General Surgery, School of Medicine, Tabriz University of Medical Sciences, Tabriz, Iran

Abstract
Introduction: Liver transplantation is a life-saving treatment for end-stage liver disease, but its success depends heavily on accurate pathologic assessment before, during, and after surgery. Pathology helps define native liver disease, assess donor organ quality, and identify causes of graft dysfunction. The aim of this study was to evaluate the pathologic findings in patients undergoing liver transplantation.

Material and methods: This retrospective descriptive cross-sectional study was conducted at Imam Reza Hospital, Tabriz, on 73 liver transplant patients selected by convenience sampling based on the Cochran formula. Data were extracted from archived medical records and pathology reports, and included demographic characteristics, transplant indications, explant pathology, and available post-transplant histopathologic findings to evaluate the spectrum of pathologic changes in this patient population.

Results: Among 73 liver transplant recipients, cirrhosis was the leading transplant indication (32.9%) and the dominant explant finding (71.2%), while advanced fibrosis/cirrhosis was present in 75.3%. Steatosis was identified in 31.5%, cholestasis in 23.3%, and hepatocellular carcinoma in 19.2%. Hepatocellular carcinoma was significantly associated with older age (P = 0.041), viral hepatitis (P = 0.018), pre-transplant cirrhosis (P = 0.047), dysplasia (P = 0.006), vascular abnormalities (P = 0.039), and microvascular invasion (P < 0.001).

Conclusion: These findings indicate that end-stage cirrhotic liver disease constitutes the principal pathologic burden in liver transplant recipients, while hepatocellular carcinoma represents a clinically important subset linked to adverse pathologic features. Careful explant pathologic evaluation is therefore essential not only for confirming the underlying disease spectrum but also for identifying malignant and high-risk microscopic characteristics with prognostic relevance.

Graphical Abstract

Pathologic Evaluation in Patients Undergoing Liver Transplantation

Keywords

Subjects

[1]       Amado, V., Rodríguez-Perálvarez, M., Ferrín, G., & De la Mata, M. (2018). Selecting patients with hepatocellular carcinoma for liver transplantation: Incorporating tumor biology criteria. Journal of Hepatocellular Carcinoma, 6, 1–10.
[2]       Bhat, M., Rabindranath, M., Chara, B. S., & Simonetto, D. A. (2023). Artificial intelligence, machine learning, and deep learning in liver transplantation. Journal of Hepatology, 78, 1216–1233.
[3]       Brown, Z. J., Tsilimigras, D. I., Ruff, S. M., Mohseni, A., Kamel, I. R., Cloyd, J. M., et al. (2023). Management of hepatocellular carcinoma: A review. JAMA Surgery, 158, 410–420.
[4]       Duffy, J. P., Vardanian, A., Benjamin, E., Watson, M., Farmer, D. G., Ghobrial, R. M., et al. (2007). Liver transplantation criteria for hepatocellular carcinoma should be expanded: A 22-year experience with 467 patients at UCLA. Annals of Surgery, 246, 502–509.
[5]       Guiteau, J. J., Cotton, R. T., Washburn, W. K., Harper, A., O’Mahony, C. A., Sebastian, A., et al. (2010). An early regional experience with expansion of Milan criteria for liver transplant recipients. American Journal of Transplantation, 10, 2092–2098.
[6]       Hameed, B., Mehta, N., Sapisochin, G., Roberts, J. P., & Yao, F. Y. (2014). Alpha-fetoprotein level > 1000 ng/mL as an exclusion criterion for liver transplantation in patients with hepatocellular carcinoma meeting the Milan criteria. Liver Transplantation, 20, 945–951.
[7]       Jamtani, I., Lee, K. W., Choi, Y., Choi, Y., Lee, J. M., Han, E. S., et al. (2021). Tailored prediction model of survival after liver transplantation for hepatocellular carcinoma. Journal of Clinical Medicine, 10, 2869.
[8]       Kim, S. J., & Kim, J. M. (2022). Prediction models of hepatocellular carcinoma recurrence after liver transplantation: A comprehensive review. Clinical and Molecular Hepatology, 28, 739–753.
[9]       Lingiah, V. A., Niazi, M., Olivo, R., Paterno, F., Guarrera, J. V., & Spyropoulos, N. T. (2020). Liver transplantation beyond Milan criteria. Journal of Clinical and Translational Hepatology, 8, 69–75.
[10]    Mazzaferro, V., Llovet, J. M., Miceli, R., Bhoori, S., Schiavo, M., Mariani, L., et al. (2009). Metroticket Investigator Study Group: Predicting survival after liver transplantation in patients with hepatocellular carcinoma beyond the Milan criteria: A retrospective, exploratory analysis. The Lancet Oncology, 10, 35–43.
[11]    Mazzaferro, V., Regalia, E., Doci, R., Andreola, S., Pulvirenti, A., Bozzetti, F., et al. (1996). Liver transplantation for the treatment of small hepatocellular carcinomas in patients with cirrhosis. The New England Journal of Medicine, 334, 693–699.
[12]    Nagy, G., Gerlei, Z., Haboub-Sandil, A., Görög, D., Szabó, J., Kóbori, L., et al. (2022). Optimizing survival for hepatocellular carcinoma after liver transplantation: A single-center report and current perspectives. Transplantation Proceedings, 54, 2593–2597.
[13]    Özdemir, F., & Baskiran, A. (2020). The importance of AFP in liver transplantation for HCC. Journal of Gastrointestinal Cancer, 51, 1127–1132.
[14]    Ruch, B., Wagler, J., Kumm, K., Zhang, C., Katariya, N. N., Garcia Saenz-de-Sicilia, M., et al. (2022). Hepatocellular carcinoma, alpha fetoprotein, and liver allocation for transplantation: Past, present and future. Current Oncology, 29, 7537–7551.
[15]    Serper, M., Asrani, S., VanWagner, L., Reese, P. P., Kim, M., & Wolf, M. S. (2022). Redefining success after liver transplantation: From mortality toward function and fulfillment. Liver Transplantation, 28, 304–313.
[16]    Silva, M., Moya, A., Berenguer, M., Sanjuan, F., López-Andujar, R., Pareja, E., et al. (2008). Expanded criteria for liver transplantation in patients with cirrhosis and hepatocellular carcinoma. Liver Transplantation, 14, 1449–1460.
[17]    Sung, H., Ferlay, J., Siegel, R. L., Laversanne, M., Seromata, I., Jemal, A., et al. (2021). Global cancer statistics 2020: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA: A Cancer Journal for Clinicians, 71, 209–249.
[18]    Terrault, N. A., Francoz, C., Berenguer, M., Charlton, M., & Heimbach, J. (2023). Liver transplantation 2023: Status report, current and future challenges. Clinical Gastroenterology and Hepatology, 21, 2150–2166.
[19]    Toniutto, P., Fumolo, E., Fornasiere, E., & Bitetto, D. (2021). Liver transplantation in patients with hepatocellular carcinoma beyond the Milan criteria: A comprehensive review. Journal of Clinical Medicine, 10, 3932.
[20]    Toso, C., Asthana, S., Bigam, D. L., Shapiro, A. M., & Kneteman, N. M. (2009). Reassessing selection criteria prior to liver transplantation for hepatocellular carcinoma utilizing the Scientific Registry of Transplant Recipients database. Hepatology, 49, 832–838.
[21]    Toso, C., Trotter, J., Wei, A., Bigam, D. L., Shah, S., Lancaster, J., et al. (2008). Total tumor volume predicts risk of recurrence following liver transplantation in patients with hepatocellular carcinoma. Liver Transplantation, 14, 1107–1115.
[22]    Vogel, A., Meyer, T., Sapisochin, G., Salem, R., & Zaborowski, A. (2022). Hepatocellular carcinoma. The Lancet, 400, 1345–1362.
[23]    Xu, X., Lu, D., Ling, Q., Wei, X., Wu, J., Zhou, L., et al. (2016). Liver transplantation for hepatocellular carcinoma beyond the Milan criteria. Gut, 65, 1035–1041.
[24]    Yao, F. Y., Ferrell, L., Bass, N. M., Watson, J. J., Bacchetti, P., Venook, A., et al. (2001). Liver transplantation for hepatocellular carcinoma: Expansion of the tumor size limits does not adversely impact survival. Hepatology, 33, 1394–1403.
[25]    Yao, F. Y., Xiao, L., Bass, N. M., Kerlan, R., Ascher, N. L., & Roberts, J. P. (2007). Liver transplantation for hepatocellular carcinoma: Validation of the UCSF-expanded criteria based on preoperative imaging. American Journal of Transplantation, 7, 2587–2596.